Denali Therapeutics (DNLI) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 6 Phase 2[2], 4 Phase 1[3].
Trial NCT06075537[5] evaluates tividenofusp alfa in Mucopolysaccharidosis II with a target enrollment of 99 participants. Trial NCT05371613[6] evaluates tividenofusp alfa in Mucopolysaccharidosis II with a target enrollment of 63 participants.
No Form 4 insider filings for DNLI were recorded at the SEC in the past 30 days[7].